{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T11:40:06Z","timestamp":1743075606209,"version":"3.40.3"},"reference-count":5,"publisher":"BMJ","issue":"e2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2024,2,3]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>The management of seizures at the end of life is vital for patient comfort and to reduce carer distress. The use of high -dose subcutaneous benzodiazepines is standard, but not always effective. We present a case where lacosamide was used subcutaneously to prevent seizure activity.<\/jats:p>","DOI":"10.1136\/spcare-2023-004699","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T18:20:11Z","timestamp":1708539611000},"page":"e1795-e1796","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Subcutaneous lacosamide for seizures"],"prefix":"10.1136","volume":"14","author":[{"given":"Natalie","family":"McCarthy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7094-7783","authenticated-orcid":false,"given":"Elizabeth","family":"Freshwater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nial","family":"McCarron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"2025032703260728000_14.e2.e1795.1","unstructured":"Clinical knowledge summary: epilepsy. NICE; 2023. Available: https:\/\/cks.nice.org.uk\/topics\/epilepsy\/ [Accessed 15 Oct 2023]."},{"key":"2025032703260728000_14.e2.e1795.2","doi-asserted-by":"crossref","unstructured":"Oliveira M , Lime E , et al . Factors associated with caregiver burden of adults with epilepsy in a middle-income country, Available: https:\/\/doi.org\/10.1016\/j.seizure.2022.03.015","DOI":"10.1016\/j.seizure.2022.03.015"},{"key":"2025032703260728000_14.e2.e1795.3","unstructured":"British national Formulary 86. 2023. Available: https:\/\/www.nice.org.uk\/bnf-uk-only [Accessed 15 Oct 2023]."},{"key":"2025032703260728000_14.e2.e1795.4","first-page":"3687","article-title":"Effects of levetiracetam and lacosamide on therapeutic efficacy and neural function in patients with epilepsy","volume":"20","author":"Liu","year":"2020","journal-title":"Exp Ther MED"},{"key":"2025032703260728000_14.e2.e1795.5","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.jpainsymman.2015.11.001","article-title":"Subcutaneous use of lacosamide","volume":"51","author":"R\u00e9mi","year":"2016","journal-title":"J Pain Symptom Manage"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2023-004699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T11:02:20Z","timestamp":1743073340000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2023-004699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":5,"journal-issue":{"issue":"e2","published-online":{"date-parts":[[2024,11,15]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/spcare-2023-004699"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2023-004699","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"type":"print","value":"2045-435X"},{"type":"electronic","value":"2045-4368"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}